androstane and Lung-Neoplasms

androstane has been researched along with Lung-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for androstane and Lung-Neoplasms

Article	Year
The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites. Materials science & engineering. C, Materials for biological applications, 2018, Aug-01, Volume: 89 An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d Topics: A549 Cells; Androstanes; Calorimetry, Differential Scanning; Cell Line; Cell Survival; Chitosan; Drug Carriers; Drug Liberation; Durapatite; Humans; Lactic Acid; Lung Neoplasms; Microscopy, Atomic Force; Nanocomposites; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared	2018

Article

Year

The effect of the androstane lung cancer inhibitor content on the cell-selective toxicity of hydroxyapatite-chitosan-PLGA nanocomposites.

Materials science & engineering. C, Materials for biological applications, 2018, Aug-01, Volume: 89

An androstane (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (derivative A)) cancer inhibitor was successfully captured in a carrier made of nano-sized hydroxyapatite (HAp) coated with chitosan-PLGA polymer blends (Ch-PLGA). In our previous studies, we demonstrated that it was convenient to use spherical HAp/Ch-PLGA carriers as vehicles to target the lungs following intravenous administration. In this study, we used emulsification and subsequent freeze-drying to load the spherical HAp/Ch-PLGA carriers with varying contents of the derivative A, in order to examine the selective toxicity towards cancerous/healthy lung cells. The XRD and FT-IR techniques confirmed the drug loading process, and the content of the poorly water soluble derivative A was estimated directly via the DSC technique. The particles were spherical in shape with the d

Topics: A549 Cells; Androstanes; Calorimetry, Differential Scanning; Cell Line; Cell Survival; Chitosan; Drug Carriers; Drug Liberation; Durapatite; Humans; Lactic Acid; Lung Neoplasms; Microscopy, Atomic Force; Nanocomposites; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared

2018